- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02783053
Metformin and Core Temperature in Obese and Lean Males (McTOM)
Metformin is known to increase 18F-FDG uptake in subjects using metformin in retrospective trials.
In this study the researchers aim to investigate the influence of metformin (500 mg 1/day) on temperature in the colon, glucose uptake in the colon and energy expenditure in healthy lean (BMI < 24kg/m2) or obese subjects (BMI>28kg/m2). The investigators will measure 18F-FDG uptake in the colon, temperature in the colon, insulin sensitivity and energy expenditure before after using metformin.
Studieoversigt
Detaljeret beskrivelse
Obesity and diabetes mellitus type 2 (DM2) are health problems with a tremendous impact. Many attempts have been made to combat obesity and DM2, however, a breakthrough therapy is still lacking.
Obesity is the result of an imbalance between energy intake and energy expenditure. 18F-fluorodeoxy-d-glucose (18F-FDG) positron emission tomography computed tomography (PET-CT) pinpoint areas with high glucose turnover. Physiological 18F-FDG accumulation is frequently observed in the colon. Therefore, the colon might play an important role in increasing energy expenditure by consuming calories. However, the possibility of the colon as an energy dissipating tissue has not yet been explored. The colon could become an interesting new target of research to find a method to combat obesity.
Metformin is one of the few drugs in the treatment of DM2 that is associated with moderate weight loss. Interestingly, patients using metformin show an increased 18F-FDG-uptake in the colon. Whether this higher uptake of glucose also cause an increase in core temperature and/or an increase in energy expenditure is not known. The cause for this increase in glucose uptake in the colon by metformin use is unknown. Also, it is unknown whether this increase in glucose uptake results in an increased energy expenditure and/or an increase in core body temperature.
Objective: In this study the researchers aim to investigate the influence of metformin (500 mg 1/day) on temperature in the colon, glucose uptake in the colon and energy expenditure in healthy lean (BMI < 24kg/m2) or obese subjects (BMI>28kg/m2). The investigators will measure 18F-FDG uptake in the colon, temperature in the colon, insulin sensitivity and energy expenditure before after using metformin.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Amsterdam, Holland, 1105AZ
- Academic Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male
- Caucasian origin
- Subjects should be able and willing to give informed consent
- > 50 years old
- BMI< 24 kg/m2 or > 28 kg/m2
Exclusion Criteria:
- Renal failure (GFR< 60ml/min)
- Liver insufficiency (AST or alanine aminotransferase 3 times upper value)
- Chronic use of drugs or medication
- Diabetes mellitus
- Lactate acidosis or precoma diabeticum in medical history
- Acute or chronic diseases such as: dehydration, severe infection, shock, heartfailure, pulmonary insufficiency, recent heart attack
- Alcoholism
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Diagnostisk
- Tildeling: Ikke-randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Andet: Metformin use
The investigators compare the use of metformin vs no metformin
|
Metformin vs no metformin
|
Ingen indgriben: Lean or Obese
The investigators compare the effect of metformin on 18F-FDG uptake between lean and obese men.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
18F-FDG uptake
Tidsramme: 1 week
|
Difference in 18F-FDG uptake as registered by 18F-FDG PET-CT before and after 7 days of daily metformin use.
|
1 week
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Core temperature using a temperature pill
Tidsramme: 48 hours
|
- Difference in core body temperature before and after metformin
|
48 hours
|
Correlation core temperature and 18F-FDG uptake
Tidsramme: 1 week
|
- Correlation between 18F-FDG uptake in the colon and core temperature
|
1 week
|
Energy expenditure (kcal/day) using ventilated hood
Tidsramme: 30 minutes
|
- Difference in energy expenditure before and after metformin use
|
30 minutes
|
Correlation between 18F-FDG uptake and energy expenditure
Tidsramme: 1 week
|
- Correlation between difference inenergy expenditure and 18F-FDG uptake in the colon
|
1 week
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- METC2015_117
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Metformin
-
Anji PharmaSuspenderetDiabetes mellitus, type 2Spanien, Forenede Stater, Canada, Ungarn, Brasilien, Tjekkiet, Polen, Bulgarien
-
NuSirt BiopharmaAfsluttetType 2 diabetes mellitusForenede Stater
-
ShionogiAfsluttet
-
Bristol-Myers SquibbAfsluttetType 2 diabetes mellitusSydafrika, Forenede Stater, Canada, Puerto Rico, Ungarn, Tyskland, Tjekkiet, Polen, Rumænien, Det Forenede Kongerige
-
Charles University, Czech RepublicAfsluttet
-
German Diabetes CenterYale UniversityTilmelding efter invitation
-
Hoffmann-La RocheAfsluttetDiabetes mellitus type 2Forenede Stater, Mexico, Argentina
-
Hadassah Medical OrganizationTrukket tilbage
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceAktiv, ikke rekrutterendeType 2 diabetes mellitus | Præ-diabetesAustralien
-
Woman'sPfizer; American Cancer Society, Inc.; Our Lady of the Lake Regional Medical...Trukket tilbageInsulin resistens | Brystkræftstadiet | Racemæssig skævhedForenede Stater